The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8.sup.+ TILs, relative to CD4.sup.+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof.

[00001]$17667030.1$

Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.

Stabilized amorphous calcium carbonate (ACC) for treatment of several neurological, muscular and infertility diseases and conditions is provided. In particular, the stabilized ACC may be used in the treatment of axonal defects and muscular dystrophy. In addition, provided are improved methods used in assistant reproductive technology. Examples of such methods are in vitro fertilization and improvement of sperm quality. The improved IVF method, for example, comprises addition of the stabilized ACC to the cell culture medium in which the stages of fertilization and embryo development occurs.

Provided is a method of preparing a hydrogel composition including a uniform content of calcium phosphate, wherein a hydrogel composition prepared by the method has a uniform content of calcium phosphate, and thus may be used to quantify phosphates contained in the hydrogel composition. Provided is an in-vitro 3D osteoporosis model including a calcium phosphate hydrogel composition, wherein osteoblasts and osteoclasts may be three-dimensionally co-cultured inside a biogel, such that the osteoporosis model may be fabricated according to an intended use or clinical stage. Further, the model contains a calcium phosphate hydrogel with a uniform content of phosphate and thus enables quantification of calcium phosphate through measurement of phosphates, and therefore, the model may be used to screen candidate compounds for an osteoporosis drug and may effectively predict therapeutic effects of the drug on osteoporosis.

Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O.sub.2 tension, including manipulation of Ca.sup.2+ under high O.sub.2 tension and contacting oocytes with serine threonine kinase inhibitors under low O.sub.2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O.sub.2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.

The present invention relates to a Lactobacillus sakei CVL-001 strain and a method for isolating same, wherein the strain is lactic acid bacteria which can be isolated from kimchi, and thus can be effectively used as a probiotic or food additive. Furthermore, the present invention relates to a composition for improving, preventing, or treating bone diseases or metabolic diseases, including Lactobacillus sakei CVL-001 strain (Lactobacillus sakei) or a culture medium thereof, wherein the Lactobacillus sakei strain isolated from kimchi and the culture medium thereof exhibit the effects of suppressing osteoclast differentiation, improving osteoporosis, suppressing adipocyte differentiation, and suppressing weight gain, and thus can be effectively used for the improvement, prevention, or treatment of osteoporosis or obesity related diseases.

Plant cell cultures as well as related methods, systems, and compositions for increasing the frequency and efficiency of plant genome editing are provided. Various plant cell growth conditions and/or treatments where such increases in gene editing frequencies are obtained are disclosed.

The present disclosure provides compositions and methods comprising human platelet releasate (hPR), a xeno-free media supplement. The disclosure also relates to a cGMP process for the rapid, efficient and large-scale manufacturing of hPR that may be performed in less than 4 hours. The platelet releasate of the current disclosure prevents gelation of growth media alleviating the need for heparin or other anticoagulants. Mesenchymal stem cells expanded in the presence of platelet releasate have demonstrated superior expansion rates and potency compared to commercial supplements including platelet lysates. The releasate has therapeutic and medical applications. The disclosure also relates to compositions and methods related to platelet-rich fibrin.

A synthetic meat product for human and animal consumption and methods for producing such food product are disclosed. The synthetic food product comprises or essentially consists of a cell biomass of avian cells grown in vitro in a chemically-defined serum free culture medium under controlled conditions and do not contain any hazard contaminations.

A method of manufacturing the calcium nanohydroxyapatite Ca.sub.10(PO.sub.4).sub.6(OH).sub.2 structurally modified with Li.sup.+ ions (nHAP:Li.sup.+) Li.sub.0.1Ca.sub.9.9(PO.sub.4).sub.6(OH).sub.2 optionally doped with 1-2% mol of Eu.sup.3+ cations in the form of nanocrystalline powder and use of Li.sub.0.1Ca.sub.9.9(PO.sub.4).sub.6(OH).sub.2 in regenerative medicine as an agent improving of proliferative activity of progenitor cells and demonstrating an anti-apoptotic effect on progenitor cells and in addition use of Li.sub.0.1Ca.sub.9.9(PO.sub.4).sub.6(OH).sub.2 doped with 1-2% mol Eu.sup.3+ cations as an agent improving of proliferative activity of progenitor cells and demonstrating the luminescence signal used in diagnostic application.